Our Passion, Your Health.

Fidia Presents Hymovis®, a New Generation Hyaluronan, at the ACR Annual Meeting in San Francisco

Hymovis®, which was recently approved by the FDA in the U.S., is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., Nov. 2, 2015 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will present Hymovis® (high molecular weight viscoelastic hyaluronan) at the American College of Rheumatology (ACR) Annual Meeting in San Francisco, Nov. 8-11, 2015.

Hymovis® is a new generation of HA-based intra-articular (IA) therapy indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. The product has a shorter treatment cycle of only two intra-articular injections as compared to many other IA HA viscosupplement regimens to provide pain relief for the patient.

Hymovis® is engineered using a proprietary process that results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows the molecule to recover its original structure, even after repetitive mechanical stress. The mechanical properties of Hymovis® lead to increased elasticity, viscosity and residence time in the joint.

Worldwide, hyaluronic acid-based intra-articular injections are used in the treatment of knee pain due to OA of the knee and have been recognized and included in both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) guidelines for the treatment of osteoarthritis of the knee.

The Food and Drug Administration's (FDA) Center for Devices and Radiological Health gave premarket approval (PMA) for Hymovis® on Aug. 28, 2015 and Hymovis® is expected to launch in the first quarter of 2016.

"The FDA approval will expand Fidia's presence in the U.S. and serve as global recognition of Fidia's leadership in the field of hyaluronic acid and treatment of osteoarticular pathologies," said Giorgio Foresti, CEO, Fidia Farmaceutici S.p.A.

For more information, please visit Fidia Pharma USA Inc. at the ACR Annual Meeting in booth 1400. To schedule a meeting, please call 1-973-507-5120 or email Hymovis@FidiaPharma.us.

Download press release (PDF)

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness